MRI Evaluation of Non-Necrotic T2-Hyperintense Foci in Pediatric Diffuse Intrinsic Pontine Glioma

O. Clerk-Lamalice, W.E. Reddick, X. Li, Y. Li, A. Edwards, J.O. Glass and Z. Patay

AJNR Am J Neuroradiol 2016, 37 (10) 1930-1937
doi: https://doi.org/10.3174/ajnr.A4814
http://www.ajnr.org/content/37/10/1930
ABSTRACT

BACKGROUND AND PURPOSE: The conventional MR imaging appearance of diffuse intrinsic pontine glioma suggests intralesional histopathologic heterogeneity, and various distinct lesion components, including T2-hypointense foci, have been described. Here we report the prevalence, conventional MR imaging semiology, and advanced MR imaging features of non-necrotic T2-hyperintense foci in diffuse intrinsic pontine glioma.

MATERIALS AND METHODS: Twenty-five patients with diffuse intrinsic pontine gliomas were included in this study. MR imaging was performed at 3T by using conventional and advanced MR imaging sequences. Perfusion (CBV), vascular permeability (vₑ, K\text{trans}), and diffusion (ADC) metrics were calculated and used to characterize non-necrotic T2-hyperintense foci in comparison with other lesion components, namely necrotic T2-hyperintense foci, T2-hypointense foci, peritumoral edema, and normal brain stem. Statistical analysis was performed by using Kruskal-Wallis and Wilcoxon rank sum tests.

RESULTS: Sixteen non-necrotic T2-hyperintense foci were found in 12 tumors. In these foci, ADC values were significantly higher than those in either T2-hypointense foci (\( P = .002 \)) or normal parenchyma (\( P = .0002 \)), and relative CBV values were significantly lower than those in either T2-hypointense (\( P = .0002 \)) or necrotic T2-hyperintense (\( P = .006 \)) foci. Volume transfer coefficient values in T2-hyperintense foci were lower than those in T2-hypointense (\( P = .0005 \)) or necrotic T2-hyperintense (\( P = .0348 \)) foci.

CONCLUSIONS: Non-necrotic T2-hyperintense foci are common, distinct lesion components within diffuse intrinsic pontine gliomas. Advanced MR imaging data suggest low cellularity and an early stage of angioneogenesis with leaky vessels resulting in expansion of the extracellular space. Because of the lack of biopsy validation, the underlying histoarchitectural and pathophysiologic changes remain unclear; therefore, these foci may correspond to a poorly understood biologic event in tumor evolution.

ABBREVIATIONS: DCE = dynamic contrast-enhanced; DIPG = diffuse intrinsic pontine glioma; K\text{trans} = volume transfer coefficient; rCBV = relative cerebral blood volume; T2HoF = T2-hyperintense foci; T2HrF = T2-hypointense foci; vₑ = fractional volume of the extravascular extracellular space.

Most pediatric brain stem tumors are of glial origin. The largest subgroup of brain stem gliomas is diffusely infiltrative; those originating from the pons are referred to as diffuse intrinsic pontine glioma (DIPG), and their outcomes are among the worst in pediatric neuro-oncology, with a median survival of 1 year from diagnosis.2-4

The diagnosis of DIPG relies heavily on conventional MR imaging, which has remarkably high accuracy for this purpose (approximately 95%-97%). The typical DIPG appears as a poorly marginated, intra-axial mass lesion that is centered on the ventral pons, involves >70% of the cross-sectional area of the brain stem, and exhibits ventral exophytism with or more less engulfment of the basilar artery.

The MR imaging appearance of DIPG suggests intralesional heterogeneity, and it is conceivable that all apparent lesion components and areas in heterogeneous tumors may not have the same pathologic relevance and diagnostic imaging significance. The prognostic value of conventional MR imaging features is controversial. Recently, investigators found that ring enhancement and small tumor size at diagnosis are associated with poor outcome.5,6 Other MR imaging features, such as necrosis, intratumoral hemorrhage, and tumor extensions beyond the pons, while important at diagnosis, were not found to have predictive value for outcomes, likely because they are nonspecific for neoplastic processes and difficult to interpret, representing crude, indirect approximations of actual changes in tumor biology and burden.7
Alternatively, advanced imaging characterization of distinct lesion components (“building blocks”) with potentially distinct histopathologic and/or pathophysiologic interpretation may be more valuable, allowing a more direct and selective modular approach to the imaging evaluation of DIPG.

Several distinct lesion components or MR imaging features reflecting different forms or types of lesion heterogeneity in DIPG and other tumors, such as cysts, necrosis, and edema, have been described. Furthermore, intratumoral T2-hypointense foci (T2HoF) characterized by low ADC and high CBV values have been reported in 11.6% of patients and have been putatively attributed to foci of anaplasia. Also, a peculiar form of postcontrast T1 signal enhancement (“occult enhancement”) has been described in subtraction postcontrast T1-weighted images and was found to be associated with increased CBV; hence, this type of enhancement is thought to correspond to the MR imaging sub-strate of intratumoral angioeneogenesis.

A systematic review of a cohort of pediatric patients enrolled in a clinical trial for the treatment of DIPG led us to recognize a previously unreported lesion component in DIPG: solitary or multiple, relatively well-defined, intratumoral, non-necrotic T2-hyperintense foci (T2HiF) that are typically associated with local mass effect. We, therefore, set out to evaluate and describe the prevalence, conventional MR imaging semiology, and advanced MR imaging features of non-necrotic T2HiF in DIPG in comparison with those of T2HoFnecrotic T2HiF, peritumoral edema, and normal brain stem.

**MATERIALS AND METHODS**

**Patients**

We reviewed and analyzed the baseline conventional and advanced MR imaging data of patients with newly diagnosed DIPG who were enrolled in an institutional review board–approved prospective phase I clinical trial (PDGFR [platelet-derived growth factor receptor] Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma [SJPDGF]) in our institution between July 2011 and December 2013. The primary objective of that clinical trial was to evaluate the toxicity of crenolanib, an inhibitor of platelet-derived growth factor receptor–kinase, in children and young adults with newly diagnosed DIPG (or recurrent, progressive, or refractory high-grade gliomas, including DIPG). Consent was obtained from patients or legal representatives before enrollment. The full trial protocol is available on-line (http://clinicaltrials.gov/ct2/show/NCT01393912).

Twenty-eight patients with newly diagnosed DIPG were initially enrolled in the SJPDGF study; however, after reviewing the available images, advanced MR imaging datasets, and the participants’ medical records, we excluded 3 patients from the current study. Two patients were excluded because the MR imaging features and clinical evolution were uncharacteristic of DIPG and, in retrospect, more suggestive of a lower grade astrocytoma (ie, the patient was still alive 3 years after the initial diagnosis; tumor regressed and was stable after treatment). One other patient was excluded because of a very hemorrhagic tumor, which led to suboptimal DSC perfusion MR imaging datasets. Thus, 25 patients were included in the current study (14 females and 11 males; mean age, 6.94 years; age range, 2.08–17 years). No biopsies were performed; therefore, no histopathologic data were available for any of these patients at enrollment.

**Normative MR Imaging Data of the Pons**

To establish normative diffusion and DSC perfusion values for the pons in children, we used advanced MR imaging data from an age-matched (mean age, 5.23 years; age range, 2–12 years) cohort of patients (n = 17) who had MR imaging studies for supratentorial CNS malignancies (5 pineoblastomas, 1 ependymoma, 1 astrocytoma, 1 anaplastic ganglioma, 1 choroid plexus carcinoma, 1 high-grade glioma, 3 primitive neuroectodermal tumors, and 4 atypical teratoid/rhabdoid tumors) at the time of initial diagnosis and who had no visible structural abnormalities in the posterior fossa. Conventional MR images were screened for any visible abnormality before analysis of advanced MR imaging data, and findings were unremarkable. The small SD of the ADC and CBV values in this cohort suggests homogeneity of the normative dataset.

**Conventional MR Imaging and IV Contrast Injection**

While patients were under sedation or general anesthesia, all MR imaging studies were performed on 3T scanners (Magnetom Trio or Skyra; Siemens, Erlangen, Germany) by using 32-channel (Trio) or 20-channel (Skyra) phased array head coils. The standard conventional MR imaging protocol included axial T2-weighted turbo spin-echo (TR/TE = 3800/83 ms), pre- and postcontrast axial T1-weighted gradient-echo (TR/TE = 236/2.31 ms), and postcontrast FLAIR (TR/TE = 10,000/108 ms; TI = 2600 ms) sequences with a section thickness of 4 mm. Axial susceptibility-weighted images (TR/TE = 56/25 ms) had a section thickness of 2 mm. A total of 0.2 mL/kg (0.1 mmol/kg) of gadopentetate dimeglumine (Magnevist; Bayer HealthCare Pharmaceuticals, Wayne, New Jersey) was administered in all patients in 2 equally divided doses for the dynamic contrast-enhanced (DCE) and DSC perfusion MR imaging studies (see below) before performing the postcontrast T1-weighted imaging sequences. In all cases and for all contrast-enhanced sequences, Gd-DTPA was injected intravenously at a rate of 2 mL/s through a 22-ga IV catheter by using an infusion pump synchronized with the MR imaging scanner. A saline flush of 20 mL also administered at a rate of 2 mL/s, followed each Gd-DTPA injection.

**Advanced MR Imaging**

**DCE-MR Imaging.** First, 3 series of 3D gradient-echo images were collected to calculate TI maps in the brain parenchyma (TR/TE = 5.3/3.2 ms; flip angle = 2°, 10°, and 20°). Subsequently, a total of 50 dynamic series of 16 images covering the brain stem and posterior fossa were acquired by using a 3D gradient-echo sequence with parallel imaging (TR/TE = 5/3.2 ms, generalized autocalibrating partially parallel acquisition accelerating factor R = 2, 24 reference lines, average = 1, flip angle = 15°, 16 sections, section thickness = 4 mm [no gap]), matrix size = 128 × 128, in-plane resolution = 1.8 × 1.8 mm, temporal sampling = 6.84 seconds). The IV injection of Gd-DTPA (0.1 mL/kg) started 20 seconds after the initiation of the DCE sequence.

**DSC-MR Imaging.** The first dose of Gd-DTPA used for the DCE-MR imaging study served as preloading to allow leakage correction. DSC–MR imaging data were obtained after a sec-
ond dose of Gd-DTPA (0.1 mL/kg) was injected 10 seconds after the beginning of the DSC sequence (single-shot free induction decay EPI, TR/TE = 1900/50 ms [Trio] and 2030/52 ms [Skyra], average H11005 1, flip angle H11005 90°, 16 contiguous sections, section thickness H11005 4 mm, matrix size H11005 256 H11003 256, in-plane resolution H11005 0.82 H11003 0.82 mm, 50 image sets, temporal sampling = 2.06 seconds).

**Diffusion Imaging.** Diffusion data were acquired by using a single-shot spin-echo EPI sequence (TR/TE = 6500/120 [Trio] and 7500/120 ms [Skyra], b=700 ms, section thickness = 3 mm, no gap, matrix size = 128 × 128, in-plane resolution = 1.5 × 1.5 mm). Twelve noncoplanar, noncollinear diffusion gradient directions and 4 acquisitions were used to calculate the diffusion tensor for each voxel within the images. ADC values were derived from the DTI dataset.

**Diffusion Imaging.** Diffusion data were acquired by using a single-shot spin-echo EPI sequence (TR/TE = 6500/120 [Trio] and 7500/120 ms [Skyra], b=700 ms, section thickness = 3 mm, no gap, matrix size = 128 × 128, in-plane resolution = 1.5 × 1.5 mm). Twelve noncoplanar, noncollinear diffusion gradient directions and 4 acquisitions were used to calculate the diffusion tensor for each voxel within the images. ADC values were derived from the DTI dataset.

**Diffusion Imaging.** Diffusion data were acquired by using a single-shot spin-echo EPI sequence (TR/TE = 6500/120 [Trio] and 7500/120 ms [Skyra], b=700 ms, section thickness = 3 mm, no gap, matrix size = 128 × 128, in-plane resolution = 1.5 × 1.5 mm). Twelve noncoplanar, noncollinear diffusion gradient directions and 4 acquisitions were used to calculate the diffusion tensor for each voxel within the images. ADC values were derived from the DTI dataset.

**Image Analysis: Conventional MR Images** Conventional MR images were jointly evaluated on a PACS workstation by a board-certified neuroradiologist (25 years of experience interpreting pediatric MR imaging studies) and a radiology resident (3 years of experience interpreting pediatric brain MR imaging stud-

**Postprocessing of Advanced MR Imaging Data** Quantitative T1 maps, calculated from the variable flip angle images acquired before IV contrast administration, were used with a 2-compartment pharmacokinetic model13 and an experimentally derived population-based arterial input function,14 to analyze the DCE dataset and generate parametric maps of volume transfer coefficient (Ktrans) and fractional volume of the extravascular extracellular space (ve).

For the DSC perfusion datasets, an iterative automated process by using a Kohonen self-organizing map was used to identify

---

**FIG 1.** Axial MR images centered on the pons and showing non-necrotic T2HrF (long arrow). T2-weighted image (A), ADC map (B), T1-weighted postcontrast subtraction image (C), and CBV map (D). These images show a well-defined, fairly voluminous T2HrF within the left hemipons (a smaller similar lesion may be present on the right side, too), which is associated with mass effect, slightly increased signal in ADC (B), lack of contrast enhancement after IV gadolinium injection (C), and moderately increased CBV (D).

**FIG 2.** Axial (A) and sagittal (B) T2-weighted MR images of a DIPG with both non-necrotic T2HrF (arrowhead) and T2HoF (long arrow).
the arterial input function from a constrained set of images at the level of the basilar artery. Additional DSC perfusion MR imaging data-processing was performed by a truncated, single-value deconvolution combined with a standard Tikhonov regularization and generalized cross-validation to yield parametric maps of CBV.

Voxelwise calculations of the diffusion datasets were performed by using the DTI toolkit in SPM8 (http://www.fil.ion.ucl.ac.uk/spm/). Parametric maps of ADC values were generated from these datasets.

Segmentation of the entire tumor lesion area in the pons was performed on axial T2-weighted images by using an in-house-developed C++ program.

To allow us to work in a common space and retrieve advanced imaging data, we coregistered raw images obtained from the DCE, DSC, and diffusion acquisitions to respective T2-weighted images by using FSL (http://www.fmrib.ox.ac.uk/fsl). To accommodate misregistration between T2 and echo-planar images, we used a kernel of $5 \times 5$ to erode the pons ROI to ensure alignment with the spatially normalized parametric maps.

**Image Analysis: Advanced MR Imaging**

The mean and SD of each advanced MR imaging parameteric value were calculated for 4 types of ROIs within the pontine tumor lesion: non-necrotic T2\textsubscript{HoF}, T2\textsubscript{HoF}, necrotic T2\textsubscript{HoF}, and “none of the previous” (believed to correspond to edema). Also, mean normative ADC and CBV values for the entire pons of control patients were calculated.

All ROIs were manually drawn on T2 images by using in-house software coded in C++. Visual inspection of postcontrast T1 images was performed, when useful, to help more confidently classify and delimit the different foci. If a T2-hypointense or -hyperintense focus was appreciated on multiple axial T2 images, then the image passing by the center of the lesion was used to draw the representative ROI. We also calculated the mean sizes of all ROIs.

The ROIs drawn were then superimposed on the coregistered ADC, CBV, $K_{trans}$, and $\nu_c$ maps to calculate the mean values of each corresponding focus. To reduce CBV value variations related to technical and physiologic variations among patients, we created relative CBV (rCBV) values by normalizing CBV values within the ROIs to those of ROIs placed within normal-appearing cerebellar white matter. This normalization was performed by using an ROI drawn at the level of one of the middle cerebellar peduncles on axial T2 images and subsequently coregistered with CBV perfusion maps.

**Statistical Analysis**

Perfusion (rCBV), tissue permeability ($\nu_c$, $K_{trans}$), and diffusion (ADC) metrics of the 4 ROI types were calculated and used in conjunction with normative brain stem values to characterize each of the 4 types of ROIs. The Kruskal-Wallis test was used to evaluate whether ADC, rCBV, $K_{trans}$, and $\nu_c$ values were significantly different among the different ROI types. Pair-wise comparisons through a Wilcoxon rank sum test adjusted by Bonferroni multiple testing correction were also performed. A $P$ value $<.05$ was considered significant. Bidimensional and volumetric tumor measurements and ROI areas are reported as mean values ± SD (range). Poisson regression models were used to determine whether there was any association between the patient’s age or tumor size and the number of non-necrotic T2\textsubscript{HoF}. All statistical analyses were performed by using SAS 9.3 software (SAS Institute, Cary, North Carolina).

**RESULTS**

**Conventional MR Imaging Results**

Data from 25 tumors were used in this study. In all, 16 non-necrotic T2\textsubscript{HoF} were found in 12 patients (48% of patients); of these 12 patients, 2 patients had 2 T2\textsubscript{HoF} and 1 had 3 T2\textsubscript{HoF}. Furthermore, 13 T2\textsubscript{HoF} were found in 8 patients (32%), and 9 necrotic T2\textsubscript{HoF} were found in 8 patients (32%) at initial diagnosis. The mean of non-necrotic T2\textsubscript{HoF}, T2\textsubscript{HoF}, and necrotic T2\textsubscript{HoF} were 299.19 ± 358.40 mm$^2$ (range, 24.22–1086.08 mm$^2$), 367.10 ± 450.74 mm$^2$ (range, 40.37–1249.60 mm$^2$), and 1216.18 ± 1215.06 mm$^2$ (range, 102.28–2788.49 mm$^2$), respectively.

The mean bidimensional measurements of the tumors were 4.48 ± 0.67 cm (range, 2.78–5.97 cm) × 3.62 ± 0.65 cm (range, 2.72–5.22 cm). The mean pontine tumor volume in our cohort was 29.65 ± 9.21 cm$^3$ (range, 9.56–49.56 cm$^3$). In addition to conventional features of DIPG (poorly marginated intra-axial mass lesion, involving >70% of the cross-sectional area of the pons, exhibiting ventral exophytism with, in some cases, engulfment of the basilar artery), we found that 12 patients (48%) had noticeable signal enhancement on conventional postcontrast T1-weighted images. In addition, no association was seen between the number of non-necrotic T2 foci and age ($P = .1297$) or tumor size ($P = .5727$).

**Advanced MR Imaging Results**

The Table shows the quantitative values (mean ± SD) for each of the 4 advanced MR imaging–based surrogate biomarkers (ADC, rCBV, $K_{trans}$, $\nu_c$) in all 4 ROI categories: peritumoral edema, non-necrotic T2\textsubscript{HoF}, T2\textsubscript{HoF}, and necrotic T2\textsubscript{HoF}. For normal brain stem parenchyma, only ADC and rCBV data were available.

ADC values in non-necrotic T2\textsubscript{HoF} were significantly higher than those in T2\textsubscript{HoF} ($P = .002$) or even normal brain parenchyma ($P = .0002$) and quite similar to values in peritumoral edema. Relative CBV values in non-necrotic T2\textsubscript{HoF} were significantly lower than those in T2\textsubscript{HoF} ($P = .0002$) or necrotic T2\textsubscript{HoF} ($P = .006$), similar to those in normal brain stem parenchyma and somewhat higher than those in perilesional edema. $K_{trans}$ values in T2\textsubscript{HoF} were significantly lower than those in T2\textsubscript{HoF} ($P = .0005$) or necrotic T2\textsubscript{HoF} ($P = .0348$) but only moderately higher than those in perilesional edema. For $\nu_c$ no significant differences were seen between non-necrotic T2\textsubscript{HoF} and other evaluated lesion components (Table and Fig 3).

**DISCUSSION**

To allow more consistency in therapeutic trials (especially multicenter ones), standardization of reproducible and quantifiable imaging criteria is indispensable. Simultaneously, there is a growing need for using more robust, quantitative advanced MR imaging–based biomarkers, which have more or
Measurement of advanced MRI-based surrogate biomarkers in 5 regions

| Region                  | ADC (×10⁻³ mm²/s) | rCBV | K<sub>trans</sub> (min⁻¹) | ν<sub>a</sub> |
|-------------------------|-------------------|------|------------------|------------|
| Normal brain stem       | 0.75 ± 0.04       | 1.36 ± 0.21 | NA      | NA         |
| Peritumoral edema       | 1.42 ± 0.27<sup>b</sup> | 1.04 ± 0.31<sup>b</sup> | 0.0028 ± 0.0020 | 0.0035 ± 0.0030 |
| Non-necrotic T<sub>2</sub>HrF | 1.48 ± 0.41<sup>c,d</sup> | 1.38 ± 0.68<sup>c,d</sup> | 0.0034 ± 0.0025<sup>c,d</sup> | 0.0057 ± 0.0042 |
| T<sub>2</sub>HrF           | 0.82 ± 0.16<sup>a</sup> | 3.82 ± 1.32<sup>a</sup> | 0.012 ± 0.007<sup>f</sup> | 0.0163 ± 0.0184<sup>a</sup> |
| Necrotic T<sub>2</sub>HrF  | 1.47 ± 0.23<sup>b</sup> | 3.61 ± 1.63<sup>b</sup> | 0.0018 ± 0.0072<sup>e</sup> | 0.0071 ± 0.0132<sup>e</sup> |

Note: —NA indicates not applicable.

<sup>a</sup> Mean values ± SD are shown. Statistical differences between groups (P < .05) are signified as follows: The asterisk indicates normal brain stem, ¥, T<sub>2</sub>HrF; ‡, necrotic T<sub>2</sub>HrF; §, edema.

FIG 3. Boxplots of ADC, rCBV, K<sub>trans</sub>, and ν<sub>a</sub> for the different ROI types analyzed in DIPG. The y-axis of boxplots was rescaled for rCBV, K<sub>trans</sub>, and ν<sub>a</sub>. Error bars represent SDs. Statistical differences between groups (P < .05) are signified as follows: The asterisk indicates normal brain stem, ¥, T<sub>2</sub>HrF; ‡, necrotic T<sub>2</sub>HrF; §, edema.

less validated histopathologic and/or pathophysiologic interpretation and which take into account microenvironmental factors such as blood supply, oxygenation, and metabolic activity, which are also known to influence drug delivery and therapeutic outcome. Recently, quantitative MR imaging–based biomarkers, which have more or less validated histopathologic and/or pathophysiologic interpretation, have become robust enough to be feasible in clinical settings. For example, DSC perfusion MR imaging–based biomarkers, rCBV in particular, are surrogate markers to quantitatively assess the vascular support system (ie, angiogenesis) in tumors. ADC is a well-established surrogate for cell density in neoplastic processes. In addition, permeability metrics, such as K<sub>trans</sub> and ν<sub>a</sub>, characterize vessel wall integrity and the flux of bulk water from intravascular space into the extracellular compartment, allowing quantitation of vessel wall leakiness and resultant vasogenic edema.

The necessary next step is recognizing that tumors are not histopathologically or pathophysiologically homogeneous; therefore, evaluating a lesion as an all-inclusive whole may “dilute” critical information. To avoid this issue, one needs to define selective, targeted ROIs and draw them on specific parts of the tumor lesion. To define relevant, meaningful ROIs, we need to improve our ability to recognize distinct building blocks of tumors (eg, clones of densely packed tumor cells, areas of angiogenesis, hemorrhage, and edema) on the basis of their conventional MR imaging appearance and to use advanced MR imaging techniques to characterize them. Previous investigators have already advocated this “modular approach” and described such “building blocks” that represent key histopathologic or pathophysiologic processes in DIPG, including T<sub>2</sub>HrF (focal anaplasia), “occult” enhancement (angiogenesis), and petechial hemorrhages. Recently, histogram analysis has been used with success to quantify intratumoral heterogeneity. Histogram-derived parameters such as skewness, kurtosis, and percentiles have been found to be useful in differentiating types of gliomas. Other investigators found that rCBV histograms correspond with glioma grades, and ADC histograms can stratify progression-free survival in glioblastomas. A similar technique has been used in DIPG to demonstrate significant intratumoral and interpatient mean diffusivity heterogeneity, and shorter overall survival was found to be associated with increased ADC histogram skewness. Although these studies have undeniable merits, in this research, we took a different approach. We believe that it is important to identify distinct “building blocks” in tumors on the basis of their conventional features, characterize those by using advanced MR imaging techniques, and provide putative histopathologic and pathophysiologic interpretations.

Our advanced MR imaging data allow some speculation about the underlying histoarchitectural and pathophysiologic mechanisms occurring intrinsically within these foci. Our data suggest that non-necrotic T<sub>2</sub>HrF are potentially evaluable distinct lesion components in DIPG (and possibly in other tumors of the CNS). Non-necrotic T<sub>2</sub>HrF appear to be more common than are T<sub>2</sub>HrF for necrotic T<sub>2</sub>HrF. Non-necrotic and necrotic T<sub>2</sub>HrF may exhibit similarities other than T2 hypersignal on conventional MR imaging, such as mass effect spaying transverse pontine fibers. However, non-necrotic T<sub>2</sub>HrF typically do not show peripheral enhancement or punctate microhemorrhagic foci, which are common in necrotic foci.
Previous work in adult supratentorial gliomas has been established by other investigators.28-30 In our study, perfusion metrics (rCBV) showed a relatively broad range within non-necrotic T2HrF. Overall, they were higher than those in edema and, in some individual cases (4 patients), than in normal brain stem parenchyma (Fig 1). Relative CBV values in non-necrotic T2HrF are not elevated as much as in T2HoF. This could be interpreted as an early stage of angioneogenesis in non-necrotic T2HrF, despite the lack of apparent “occult” enhancement.

Elevated $k^\text{trans}$ values in T2HoF and necrotic T2HrF indicate higher tumor grade.31,32 Volume transfer constants between the intravascular plasma and extravascular, interstitial compartments in non-necrotic T2HrF are somewhat higher than those in edema but not as high as those in T2HoF or necrotic T2HrF. Quite remarkably, extravascular extracellular space volume fraction ($v_e$) values increase almost linearly from edema to non-necrotic T2HrF to T2HoF to necrotic T2HrF tissues; this increase suggests a trend in global vessel wall permeability, in other words, an increasing proportion of leaky vessels, characteristic of angioneogenesis.

On the basis of this information, one cannot help speculating that non-necrotic T2HrF, T2HoF, and necrotic T2HrF, though possibly coexisting, may indicate sequential steps in the evolution of tumor cell populations (clones). We, therefore, hypothesize that non-necrotic T2HrF may be a precursor of T2HoF, which may thereafter evolve to necrotic T2HrF. Non-necrotic T2HrF would correspond to an emerging clone of cells undergoing malignant transformation, with yet relatively low density of aggressive, highly edematigenous cells, inducing early angioneogenesis. In non-necrotic T2HrF, edema may be the dominant pathophysiologic phenomenon associated with expansion of the extracellular space and the resultant local mass effect. As cellular density increases, a T2HoF develops and angioneogenesis leads to a dense microvascular network, which is seen as occult enhancement in postcontrast subtraction T1-weighted images. As the vascular support system becomes insufficient, T2HoF ultimately undergo necrosis; hence, necrotic T2HrF develops (Fig 4).

**Limitations**

Besides its obvious virtues (prospective design, relatively large patient cohort), this study has several limitations, most important, the lack of histopathologic correlations and longitudinal follow-up data. In our center, diagnostic biopsies are rarely performed at the initial diagnosis of DIPG. We evaluated non-necrotic T2HrF (and other distinct lesion foci) only at baseline because all patients were enrolled in a clinical trial using a new investigational drug (crenolanib) in addition to conformal radiation therapy. These therapies are expected to alter tumor biology and hence represent confounders rendering the assessment of the natural evolution of various lesion components impossible. Therefore, our proposal of the sequential nature of the various distinct lesion foci remains speculative, though supported by advanced MR imaging data obtained by us and other investigators.

**CONCLUSIONS**

Our data and previous reports by other investigators advocate the value of the “modular” approach to the MR imaging evaluation of DIPG, by using multiparametric quantitative analysis of distinct lesion components for staging and, possibly, monitoring during treatment. We postulate that non-necrotic T2HrF are common, distinct, lesion components within DIPG. Advanced MR imaging data suggest that they are characterized by relatively low cellularity, and somewhat increased vascular permeability without substantial increase in the blood volume fraction, the latter suggesting an early stage of angioneogenesis with leaky vessels. We speculate that these foci may correspond to poorly understood biologic events in tumor evolution, pos-

![FIG 4. Feature comparison of the 4 ROIs. A, Normal brain stem. B, A non-necrotic T2HrF is a well-circumscribed intratumoral area exhibiting high T2 signal and is often associated with local mass effect on surrounding structures, shown by splaying transverse pontocerebellar fibers. C, T2HoF are characterized by low T2 signal and are locally expansile. D, Necrotic T2HrF exhibit irregular margins, central T2 hypersignal, peripheral T2 hypnosisal, and postcontrast signal enhancement. On the basis of their advanced MR imaging features, we speculate that non-necrotic T2HrF, T2HoF, and necrotic T2HrF, while possibly coexisting, may indicate sequential steps in the evolution of tumor cell populations (clones).](www.ajnr.org)
sibly representing clones of transforming cell populations evolving toward foci of anaplasia. Future work is needed to acquire histopathologic validation of our findings and the derived hypotheses and to determine the value of various distinct tumor components (eg, \( T_2^{16} \), \( T_2^{1i} \)) in the prognostication of key outcome metrics, such as progression-free survival and overall survival.

**ACKNOWLEDGMENTS**

The authors thank Cherise M. Guess, PhD, ELS, for reviewing and editing the manuscript and Edwina Anderson for data management.

Disclosures: Olivier Clerk-Lamalice—**RELATED:** National Cancer Institute,* American Lebanese Syrian Associated Charities. Zoltan Patay—**RELATED:** Grant: National Cancer Institute [PI30 CA020765]; **UNRELATED:** Travel/Accommodations/Meeting Expenses Unrelated to Activities Listed: Sao Paulo Radiological Society, European Society of Neuroradiology, Erasmus Course in MRI, European Course in Pediatric Neuroradiology, Hamad Medical Corporation, China International Forum of Pediatric Development, Indian Society of Neuroradiology, Comments: Sao Paulo Radiological Society (2013), travel and accommodations for lecturing; European Society of Neuroradiology (2015), travel and accommodations for invited lecture; European Society of Radiology (2013), travel and accommodations for lecturing; International Symposium on Neural Regeneration (2013), travel and accommodations for lecturing; *Money paid to the institution.

**REFERENCES**

1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. *Neuro Oncol* 2014;16(suppl 4):i1–iv63 CrossRef Medline

2. Warren KE. Diffuse intrinsic pontine glioma: poised for progress. *Front Oncol* 2012;2:205 CrossRef Medline

3. Broniscer A, Baker IN, Tagen M, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. *J Clin Oncol* 2010;28:4762–68 CrossRef Medline

4. Broniscer A, Baker SD, Wetmore C, et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. *Clin Cancer Res* 2013;19:3050–58 CrossRef Medline

5. Poussaint TY, Kocak M, Vajapeyam S, et al. MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). *Neuro Oncol* 2011;13:417–27 CrossRef Medline

6. Jansen MH, Veldhuizen van Zanten SE, Sanchez Aliaga E, et al. Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. *Neuro Oncol* 2015;17:160–66 CrossRef Medline

7. Hargrave D, Chuang N, Bouffet E. Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. *J Neurooncol* 2008;86:313–19 Medline

8. Lobel U, Sedlack J, Reddick WE, et al. Quantitative diffusion-weighted and dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging analysis of T2 hypointense lesion components in pediatric diffuse intrinsic pontine glioma. *AJNR Am J Neuroradiol* 2011;32:315–22 CrossRef Medline

9. Conway AE, Reddick WE, Li Y, et al. “Occult” post-counter signal enhancement in pediatric diffuse intrinsic pontine glioma is the MRI marker of angiogenesis! *Neuroradiology* 2014;56:405–12 CrossRef Medline

10. Paulson ES, Schmida KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. *Radiology* 2008;249:601–13 CrossRef Medline

11. Hu LS, Baxter LC, Pinnaduwage DS, et al. Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas. *AJNR Am J Neuroradiol* 2010;31:40–48 CrossRef Medline

12. Boxerman JL, Prah DE, Paulson ES, et al. The role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard. *AJNR Am J Neuroradiol* 2012;33:1081–87 CrossRef Medline

13. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible tracer: standardized quantities and symbols. *J Magn Reson Imaging* 1999;10:223–32 Medline

14. Parker GM, Roberts C, Macdonald A, et al. Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI. *Magn Reson Med* 2006;56:993–1000 CrossRef Medline

15. Harreld JH, Helton KJ, Kaddoum RN, et al. The effects of propofol on cerebral perfusion MRI in children. *Neuroradiology* 2013;55:1049–56 CrossRef Medline

16. Ellingson BM, Bendzus M, Boxerman J, et al. Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. *Neuro Oncol* 2015;17:1188–98 CrossRef Medline

17. Just N. Improving tumour heterogeneity MRI assessment with histograms. *Br J Cancer* 2014;111:2205–13 CrossRef Medline

18. Lobel U, Sedlack J, Sabin ND, et al. Three-dimensional susceptibility-weighted imaging and two-dimensional T2*-weighted gradient-echo imaging of intratumoral hemorrhages in pediatric diffuse intrinsic pontine glioma. *Neuroradiology* 2010;52:1167–77 CrossRef Medline

19. Just N. Histogram analysis of the microvasculature of intracerebral human and murine glioma xenografts. *Magn Reson Med* 2011;65:778–89 CrossRef Medline

20. Law M, Young R, Babb J, et al. Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. *AJNR Am J Neuroradiol* 2007;28:761–66 Medline

21. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. *Radiology* 2009;252:182–89 CrossRef Medline

22. Pope WB, Qiao XJ, Kim HJ, et al. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multicenter study. *J Neurooncol* 2012;108:491–98 CrossRef Medline

23. Steffen-Smith EA, SarlIs JE, Pierpaoli C, et al. Diffusion tensor histogram analysis of pediatric diffuse intrinsic pontine glioma. *Biomed Res Int* 2014;2014:67356 CrossRef Medline

24. Poussaint TY, Vajapeyam S, Ricci K, et al. Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. *Neuro Oncol* 2015 Oct 20. [Epub ahead of print] Medline

25. Sugahara T, Korogi Y, Kochi M, et al. Perfusion MR imaging analysis of T2 hypointense lesion components in pediatric diffuse intrinsic pontine glioma. *AJNR Am J Neuroradiol* 2014;35:29–35 CrossRef Medline

26. Lober RM, Cho YJ, Tang Y, et al. Evaluation of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with echo-planar technique in the evaluation of cellularity in gliomas. *J Magn Reson Imaging* 1999;9:53–60 Medline

27. Chen HJ, Panigrahy A, Dhall G, et al. Improved leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard. *AJNR Am J Neuroradiol* 2010;31:1879–85 CrossRef Medline

28. Al-Okaile RN, Krajka J, Wro JH, et al. Intraaxial brain masses: MR imaging–based diagnostic strategy—initial experience. *Radiology* 2007;243:539–50 CrossRef Medline

29. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR...
spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989–98 Medline
30. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490–98 CrossRef Medline
31. Cha S. Dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in pediatric patients. Neuroimaging Clin N Am 2006;16:137–47, ix CrossRef Medline
32. Roberts HC, Roberts TP, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000;21:891–99 Medline
33. Schumacher M, Schulte-Mönning J, Stoeter P, et al. Magnetic resonance imaging compared with biopsy in the diagnosis of brainstem diseases of childhood: a multicenter review. J Neurosurg 2007;106(2 suppl):111–19 CrossRef Medline
34. Yoshimura J, Onda K, Tanaka R, et al. Clinicopathological study of diffuse type brainstem gliomas: analysis of 40 autopsy cases. Neurol Med Chir (Tokyo) 2003;43:375–82; discussion 382 Medline